Astrana Health, Inc. (ASTH) earnings date, results and what the price requires
Nasdaq · SEC CIK 0001083446 · SEC filings checked Oct 17, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 6, 2026 | $972.5M | $19.7M | $0.40 | Filing |
| Mar 31, 2026 | May 7, 2026 | $965.1M | $14.4M | $0.29 | Filing |
| Dec 31, 2025 | Mar 2, 2026 | $950.5M | $7.5M | $0.12 | Filing |
| Sep 30, 2025 | Nov 6, 2025 | $956.0M | $373,000 | $0.01 | Filing |
| Jun 30, 2025 | Aug 7, 2025 | $654.8M | $9.4M | $0.19 | Filing |
| Mar 31, 2025 | May 8, 2025 | $620.4M | $6.7M | $0.14 | Filing |
| Dec 31, 2024 | Feb 27, 2025 | $665.2M | $-100,000 | $-0.14 | Filing |
| Sep 30, 2024 | Nov 7, 2024 | $478.7M | $16.1M | $0.33 | Filing |
What would Astrana Health, Inc. have to report for its valuation to change?
At $36.81, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 30.9% a year, to $3.15. On that path the next quarter needs diluted EPS near $0.01, against $0.01 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | 30.9% | 30.9% |
| EPS needed in final year | $3.15 | $3.15 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. ASTH goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.